Abstract 985P
Background
Atezo+bev is a standard of care 1L treatment for uHCC. Currently, there is no evidence to guide treatment decision-making after discontinuation of 1L atezo+bev. Therefore, we aimed to describe the real-world characteristics and outcomes in pts with uHCC who initiated 2L therapy after receiving 1L atezo+bev vs those who did not.
Methods
Oncologists from a US nationally representative network extracted electronic medical chart data for pts with uHCC who received 1L atezo+bev between June 1, 2020 and March 6, 2023. Pts were stratified into two groups based on whether they started 2L therapy within 8 weeks of 1L atezo+bev discontinuation. Pt demographic and clinical characteristics, duration of 1L treatment (DOT), and overall survival (OS) were assessed.
Results
We identified 484 eligible pts (median age, 66 years; 64.9% male; 62.6% White). At baseline, most had good performance status (ECOG PS 0–1, 79.5%) and liver function (Child-Pugh [CP]-A, 81.4%). A higher proportion of pts in the 2L (n=141) vs no 2L (n=40) cohort were White (69.5% vs 52.5%), non-Hispanic (78.0% vs 60.0%), and had Medicare/Medicaid insurance (72.3% vs 45.0%). Between 1L and 2L initiation, liver function deteriorated (CP-A, 74.5% to 52.5%) as did performance status (ECOG PS ≥2: 8.5% to 45.3%). Pts who did not initiate 2L therapy had worse performance status (ECOG PS ≥2, 52.5% vs 8.5%) and liver dysfunction (CP-B or C, 40.0% vs 25.5%). Although median 1L DOT was similar between the 2L and no 2L cohorts (6.9 vs 7.8 months), median OS from 1L initiation was nearly twice as long among 2L (26.0 months [95% CI 21.3, 27.2]) vs no 2L (14.3 months [95% CI 10.2, 24.8]) cohort pts.
Conclusions
This study provides real-world data for sequential therapy in uHCC following atezo+bev. The findings showed differences between pts initiating 2L therapy and those who did not, highlighting the need for better pt selection at the start of 1L atezo+bev and the potential benefit of timely switching from 1L atezo+bev to subsequent therapies.
Clinical trial identification
Editorial acknowledgement
Editorial assistance in the preparation of this abstract was provided by OPEN Health Scientific Communications, London, UK, with financial support from Bayer.
Legal entity responsible for the study
The authors.
Funding
Bayer.
Disclosure
A. Singal: Financial Interests, Personal, Speaker, Consultant, Advisor: Bayer, Eisai, Genentech, BMS, Exelixis, AstraZeneca, Wako Diagnostics, Exact Sciences, Roche, Glycotest, GRAIL, TARGET PharmaSolutions. K. Ozgurdal, Z. Vassilev, F. Pisa, X. Pan: Financial Interests, Personal, Full or part-time Employment: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18